Clinical trial
A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Refractory Partial Seizures (Protocol 333369-EPY-2003 [Double-blind] and Protocol 333369-EPY-2006 [Open-label Extension])
NCT00210522 is registered in ClinicalTrials.gov with SK Life Science, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Refractory Partial Seizures (Protocol 333369-EPY-2003 [Double-blind] and Protocol 333369-EPY-2006 [Open-label Extension])
- Lead sponsor
- SK Life Science, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2005
- Completion date
- June 30, 2010
- Enrollment
- 421 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.